ACS Chemical NeuroscienceNeurosciencePeer-reviewed journal article
An optonanobody for reversible photoactivation of recombinant and native alpha;7 nicotinic
Maria Vangelatou, Kian StenboltiD, Sylvie BayiD, Karima Medjebeur, Gabriel AyméiD, Pierre J. LafayeiD, Arnaud BlondeliD, Laurie PeveriniiD, Alexandre MourotiD, Pierre‐Jean CorringeriD
Abstract
Photopharmacology which enables the precise optical control of endogenous receptor activity, represents a powerful approach in neuroscience. However, photochromic diffusible ligands often exhibit limited subtype specificity, while alternative strategies for controlling specific receptor subtypes require genetic modification. Here, to achieve high subtype selectivity without the need of receptor engineering, we introduce a genetically independent strategy for optical control of endogenous receptors based on highly selective and chemically-defined photoswitchable nanobodies. By covalently coupling a light-sensitive azobenzene agonist to a high-affinity nanobody targeting 7 nicotinic acetylcholine receptor (nAChR), we engineered MalAzoCh-C4, an optonanobody that confers reversible, light-dependent activation of native 7 receptors. In Xenopus oocytes, MalAzoCh-C4 enables wavelength-controlled modulation of recombinant 7 receptors, with enhanced activity in trans configuration. In acute hippocampal slices, application of MalAzoCh-C4 produces robust photocontrol of endogenous 7 nAChRs in interneurons, sufficient to modulate action potential firing. This strategy combines nanobody specificity with the temporal resolution of photopharmacology, establishing optonanobodies as a platform for control of native neuronal receptors.
- Citations
- 1
- FWCI
- 2.09
- Field percentile
- top 12%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Development of photoactivatable drugs enables nicotinic optopharmacology
Sambashiva Banala, Matthew C. Arvin, … Luke D. Lavis·bioRxiv·Feb 5, 2018
- Optical Control Of Neuronal Activities With Photoswitchable Nanovesicles
H. Xiong, K. A. Alberto, … Z. Qin·bioRxiv·Jun 10, 2022
- Generation of nanobodies acting as silent and positive allosteric modulators of the α7 nicotinic acetylcholine receptor
Qimeng Li, Ákos Nemecz, … Pierre‐Jean Corringer·Cellular and Molecular Life SciencesPeer-reviewed·May 25, 2023
- Focal drug uncaging for the precise control of endogenous nicotinic receptors in behaving mice
Nicolas Guyon, Monir Mohayyaei, … Alexandre Mourot·bioRxiv·Oct 8, 2026
- Reversible inhibition of GluN2B-containing NMDA receptors with an in situ red-shifted, photoswitchable antagonist
Chloé Geoffroy, Romain Berraud‐Pache, … Laétitia Mony·ACS Chemical NeurosciencePeer-reviewed·Sep 6, 2024
- SNAP-tagged nanobodies enable reversible optical control of a G protein-coupled receptor via a remotely tethered photoswitchable ligand
H. Farrants, A. Acosta Ruiz, … J. Broichhagen·bioRxiv·Feb 15, 2018